据周六报道，百时美施贵宝公司（Bristol Myers Squibb）公布了1期Breakfree-1数据，显示CD 19 NEX-T CAR T疗法在自身免疫性疾病中的免疫抑制治疗中达到94%

2025-10-27 14:55

Positive, early results from 71 patients treated across three disease cohorts – systemic sclerosis, systemic lupus erythematosus and idiopathic inflammatory myopathies – are being disclosed
Across all cohorts, results support potential for immune reset, with 94% of evaluable patients remaining off chronic immunosuppressive therapy at the time of analysis
Results demonstrate BMS' steady advancement toward its goal of bringing the science of cell therapy beyond blood cancer into autoimmune diseases